• Info
  • Significant Ownership

Significant Ownership of Farallon Capital Partners, L.P.

Signature - Title
/s/ Hannah E. Dunn - Hannah E. Dunn, Managing Member of its General Partner
Location
San Francisco, CA
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Farallon Capital Partners, L.P..

Notify me when Farallon Capital Partners, L.P. files a new Schedule 13D/G report.

⭐ Subscribe ⭐

Significant Ownership of Farallon Capital Partners, L.P.

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
PTGX Protagonist Therapeutics, Inc. Common Stock, par value $0.00001 per share (the "Shares") 10% $265,004,151 5,956,488 Dapice Joshua J. 31 Dec 2024
BEAM Beam Therapeutics Inc. Common Stock, par value $0.01 per share (the "Shares") 10% $196,567,436 +$34,174,321 9,972,980 +21% Dapice Joshua J. 31 Mar 2025
SVRA Savara Inc. Common Stock, par value $0.001 per share (the "Shares") 10% $58,158,975 18,288,986 Dapice Joshua J. 31 Dec 2024
NERV Minerva Neurosciences, Inc. Common Stock, $0.0001 par value per share (the "Shares") 10% $17,160,648 4,539,854 Dapice Joshua J. 22 Dec 2025
LQDA Liquidia Corporation Common Stock, par value $0.001 per share (the "Shares") 10% $194,782,608 +$39,412,195 8,565,638 +25% Dapice Joshua J. 30 Sep 2025
AGIO AGIOS PHARMACEUTICALS, INC. Common Stock, par value $0.001 per share (the "Shares") 9.9% $166,034,875 5,674,466 Dapice Joshua J. 31 Dec 2024
ENTA ENANTA PHARMACEUTICALS INC Common Stock, par value $0.01 per share (the "Shares") 9.9% $11,953,846 2,108,262 Dapice Joshua J. 31 Dec 2024
TNGX Tango Therapeutics, Inc. Common stock, par value $0.001 per share (the "Shares") 9.7% $90,358,800 +$13,440,000 10,757,000 +17% Dapice Joshua J. 30 Sep 2025
BBNX Beta Bionics, Inc. Common Stock, $0.0001 par value per share (the "Shares") 9.7% $57,005,155 4,203,920 Dapice Joshua J. 30 Jun 2025
RVMD Revolution Medicines, Inc. Common Stock, par value $0.0001 per share (the "Shares") 7.9% $511,649,696 +$74,497,980 13,262,045 +17% Dapice Joshua J. 31 Dec 2024
ASMB Assembly Biosciences, Inc. Common Stock, par value $0.001 per shares (the "Shares") 7.3% $20,666,041 1,140,510 Dapice Joshua J. 08 Aug 2025
MEHCQ 23andMe Holding Co. Class A Common Stock, par value $0.0001 per share 6.2% $3,876,269 1,270,908 Dapice Joshua J. 13 Jun 2025
CRNX Crinetics Pharmaceuticals, Inc. Common Stock, par value $0.001 per share (the "Shares") 6% $164,477,866 5,625,098 Dapice Joshua J. 29 Aug 2025
EXEL EXELIXIS, INC. Common Stock, par value $0.001 per share (the "Shares") 5.9% $650,216,205 -$121,107,140 15,709,500 -16% Dapice Joshua J. 01 Jan 2026
GRAL GRAIL, Inc. Common Stock, par value $0.001 per share (the "Shares") 5.5% $198,678,197 +$21,146,800 2,179,684 +12% Dapice Joshua J. 17 Nov 2025
CATX Lantheus Holdings, Inc. Common Stock, par value $0.01 per share (the "Shares") 5.1% -$142,376,903 3,477,227 -42% Dapice Joshua J. 30 Sep 2025
ARMK Aramark Common Stock, Par Value $0.01 per share (the "Shares") 4.9% $562,813,955 -$145,824,331 12,899,701 -21% Dapice Joshua J. 30 Jun 2025
NYT The New York Times Company Class A Common Stock, par value $0.10 per share (the "Shares") 3.5% $314,022,385 -$190,445,639 5,609,546 -38% Dapice Joshua J. 30 Jun 2025
FBRX Forte Biosciences, Inc. Common Stock, par value $0.001 per share (the "Shares") 3.4% $12,130 221,027 Dapice Joshua J. 31 Dec 2024
ANNA AleAnna, Inc. Class A common stock, par value $0.0001 per share (the "Shares") 2.6% $12,671,224 1,068,400 Dapice Joshua J. 31 Dec 2024
ELEV Elevation Oncology, Inc. Common Stock, Par Value $0.0001 per share (the "Shares") 0% $0 -$1,305,168 0 -100% Farallon Capital Partners, L.P. 31 Mar 2025

Schedules 13D/G Reported by Farallon Capital Partners, L.P.:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.